ERBB2 and breast carcinoma: Similarly, altered expression of miR-23b-3p, miR-195-5p, miR-340-5p and miR-656-5p modulates key targets such as AKT3, CCND1, FDF2, RAF1, MYB, c-MET and PTEN, leading to trastuzumab resistance in HER2-positive breast cancer [258].